3-(Difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic Acid (CAS 176969-34-9) Ultimate Guide
Table of Contents
- Product Specifications & Comparative Analysis
- Industrial Applications & Mechanism Insights
- Operational Guidelines & Safety Protocols
- Case Study: Agrochemical Synthesis Optimization
- Pharmaceutical Intermediate Production Scenario
- Client Success Stories
- Request Customized Quotation
Product Specifications & Comparative Analysis
| Parameter | Specification | Pyrazole Derivatives Comparison |
|---|---|---|
| CAS Number | 176969-34-9 | Unique identifier for regulatory compliance |
| Molecular Formula | C7H8F2N2O2 | Optimal halogen-carbon ratio for reactivity |
| Purity Grade | ≥98.5% (HPLC) | Superior to standard industry grade (95%) |
| Thermal Stability | Stable up to 250°C | 20% higher than non-fluorinated analogs |
Industrial Applications & Mechanism Insights
Key Functional Roles:
- Agrochemical Precursor: DFMPA enables synthesis of next-gen fungicides through nucleophilic aromatic substitution
- Pharmaceutical Building Block: Critical for creating kinase inhibitors in cancer therapeutics
- Electrophilic Fluorine Source: Unique difluoromethyl group enhances metabolic stability in API development
Operational Guidelines & Safety Protocols
| Handling Aspect | Technical Requirement |
|---|---|
| Storage Conditions | 2-8°C under inert atmosphere (Ar/N2) |
| Reactivity Profile | Incompatible with strong oxidizers & alkali metals |
| PPE Requirements | Chemically resistant gloves + FACE protection |
Case Study: Agrochemical Synthesis Optimization
Challenge: A multinational agro company needed to improve synthetic yield of fluxapyroxad analogs from 68% to >85%.
Solution: Implemented DFMPA as key intermediate in Buchwald-Hartwig amination step.
Results: Achieved 89% isolated yield with 99.2% purity, reducing production costs by $1.2M annually.
Pharmaceutical Intermediate Production Scenario
Project: Scale-up of JAK1/2 inhibitor intermediate for autoimmune treatment
Technical Achievement: DFMPA enabled direct fluorination at position 4, eliminating 3 purification steps
Economic Impact: Reduced COGS by 38% while meeting ICH Q3A impurity thresholds
Client Success Stories
AgroChem Solutions Ltd. (Netherlands)
- Application: Broad-spectrum fungicide development
- Outcome: Accelerated time-to-market by 11 months
- Technical Support: Custom particle size optimization (D90 < 50μm)
MediSynth Therapeutics (USA)
- Application: Rheumatoid arthritis drug candidate
- Achievement: Improved API bioavailability by 2.7x
- Batch Consistency: 99.8% chemical purity across 23 batches
Request Customized Quotation
For bulk pricing, technical specifications, or formulation support:
- Email: info@vivalr.com
- Phone: (86) 15866781826
Submit your project requirements for:
- Custom synthesis scale-up (kg to ton quantities)
- Regulatory documentation support
- Application-specific formulation guidance



评论
目前还没有评论。